Arginase Activity - A Marker of Disease Status in Patients with Visceral Leishmaniasis in Ethiopia
Open Access
- 28 March 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Neglected Tropical Diseases
- Vol. 7 (3), e2134
- https://doi.org/10.1371/journal.pntd.0002134
Abstract
The underlying mechanisms resulting in the profound immune suppression characteristic of human visceral leishmaniasis (VL) are not fully understood. Here, we tested the hypothesis that arginase, an enzyme associated with immunosuppression, is higher in patients with VL and contributes to impaired T cell responses. We recruited patients with VL before and after treatment and healthy controls and measured the arginase metabolism in the blood of these individuals. Our results show that arginase activity is significantly higher in the blood of patients with active VL as compared to controls. These high levels of arginase decline considerably once the patients are successfully treated. We identified the phenotype of arginase-expressing cells among PBMCs as neutrophils and show that their frequency was increased in PBMCs of patients before treatment; this coincides with reduced levels of L-arginine in the plasma and decreased expression levels of CD3ζ in T cells. Leishmaniases, a group of diseases caused by a parasite, Leishmania, belong to the most neglected tropical diseases: they are mainly found in low-income countries and affect the poorest populations. These parasites infect cells of the immune system called macrophages, which can kill the intracellular parasites when they receive the right signals from other cells of the immune system, the lymphocytes. During the active phase of visceral leishmaniasis, it has been shown that lymphocytes lose their capacity to instruct the macrophages to kill the intracellular parasites. Here, we show that the levels of an enzyme, arginase, are significantly increased in the blood of patients with visceral leishmaniasis, but decrease to the same levels as those of healthy controls following successful treatment. Arginase has the capacity to deplete an amino acid, L-arginine, which is crucial for the activation of lymphocytes. Indeed, our results show that the levels of this amino acid are considerably decreased in patients with visceral leishmaniasis. Our results suggest that during the active phase of visceral leishmaniasis, increased arginase results in the depletion of L-arginine, which is responsible for the incapacity of lymphocytes to send the adequate signals to the macrophages.Keywords
This publication has 45 references indexed in Scilit:
- Local Increase of Arginase Activity in Lesions of Patients with Cutaneous Leishmaniasis in EthiopiaPLoS Neglected Tropical Diseases, 2012
- In vivo suppressive function of myeloid‐derived suppressor cells is limited to the inflammatory siteEuropean Journal of Immunology, 2011
- The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneityEuropean Journal of Immunology, 2010
- Arginase: an emerging key player in the mammalian immune systemBritish Journal of Pharmacology, 2009
- Local Suppression of T Cell Responses by Arginase-Induced L-Arginine Depletion in Nonhealing LeishmaniasisPLoS Neglected Tropical Diseases, 2009
- Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated GranulocytesCancer Research, 2009
- Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectivesImmunological Reviews, 2008
- Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancyEuropean Journal of Immunology, 2007
- Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasisThe Journal of Experimental Medicine, 2007
- Regulation of immune responses by L-arginine metabolismNature Reviews Immunology, 2005